The US Food and Drug Administration (FDA) has granted clearance to MindMotion GO, a portable neurorehabilitation product, for launch in the United States.
MindMotion GO utilizes technology that is designed to be used by patients with mild to lightly severe neurological impairments, as well as in the recovery phase of rehabilitation. Produced by the Swiss neurogaming company MindMaze, the mobile rehabilitation product is an outpatient addition to its MindMotion PRO, which received FDA approval in May 2017.
The PRO version differs from the recently approved MindMotion GO in that it is intended for use in patients with severe impairments as well as in early hospital care—in an inpatient setting—with therapeutic activities able to take place within 4 days after a neurological incident.
“Now that both MindMotion products have FDA clearance, MindMaze delivers a full spectrum of neuro-care solutions for both inpatient and outpatient recovery for patients in the United States,” said Tej Tadi, PhD, the CEO and founder of MindMaze, in a statement. “Our unique capability to safely and securely acquire data through our platform is essential for patient recovery and performance, and positions MindMaze as a powerhouse for the future of brain-machine interfaces. Beyond healthcare, this will enable powerful AI-based applications. We are working on a range of brain-tech initiatives at MindMaze to build the infrastructure for innovations to improve patients’ quality of life.”
The mobile MindMotion GO allows for real-time audio and visual feedback, aiding physicians in the assessment of progress and tailoring of therapy to their individual patient’s performance, according to MindMaze. Additionally, it enables the patients to see their progress as well. The set-up and calibration can be done in less than 5 minutes, so patients can begin rehabilitation sessions while physicians facilitate case management.
The program is equipped with a variety of gamified engaging activities which cover motor and task functions and includes a 3D virtual environment. As a result, early findings have suggested that both patient engagement and adherence to therapy have been amplified. Thus far, MindMotion GO has been trialed with upward of 300 patients across therapy centers in the UK, Italy, Germany, and Switzerland.
Neurological impairments are the main cause of long-term disability in the United States, with a recent study estimating direct and indirect costs associated with neurological diseases cost roughly $800 billion annually. For stroke alone, there are almost 800,000 cases each year, with direct annual costs estimated at $22.8 billion.
MindMaze’s Continuum of Care seeks to support earlier, and ongoing, intervention to enable by healthcare providers in the United States to have access to a cost-effective solution for improving neurorehabilitation results.
Even more resources pertaining to stroke prevention and care can be found on MD Magazine‘s new sister site, NeurologyLive.